insights_auto
Why is AGIO down 2,82%?
Dive Deeperchevron_right
AGIO:NASDAQ
Agios Pharmaceuticals Inc
27,95 USD
arrow_downward
-2,82%(-0,81) 1D
20-ноя., 14:55:06 GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AGIO...
Open
28,01 USD
High
29,14 USD
Low
27,78 USD
Mkt. cap
1,67 млд
Avg. vol.
1,13 млн
Volume
347,66 миң
52-wk high
44,07 USD
52-wk low
23,02 USD
EPS
-6,32 USD
Beta
0,66
Shares outstanding
59,81 млн
No. of employees
540
Open
28,01 USD
High
29,14 USD
Low
27,78 USD
Mkt. cap
1,67 млд
Avg. vol.
1,13 млн
Volume
347,66 миң
52-wk high
44,07 USD
52-wk low
23,02 USD
EPS
-6,32 USD
Beta
0,66
Shares outstanding
59,81 млн
No. of employees
540
News stories
From web sources and news partners
ChartMill
·
50 мүнөт мурун
S&P 500 Most Active Stocks: Netflix and Ford Lead Volume
marketscreener.com
·
47 мүнөт мурун
S&P 500, Dow Enter Correction Territory; Anthropic Tumbles Following Record Debut
Barron's
·
1 саат мурун
S&P 500’s Tech Sector Crosses Bear Market Threshold
Profile
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. Wikipedia
About Agios Pharmaceuticals Inc